Krystal Biotech, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Pittsburgh PA United States (2015)

Organization Overview

First Clinical Trial
2018
NCT03536143
First Marketed Drug
2023
beremagene geperpavec (VYJUVEK)
First NDA Approval
2023
beremagene geperpavec (VYJUVEK)
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Associate Director, Clinical Operations, Krystal Biotech | Krystal Biotech, Inc.

Active Ingredients

Marketed Drugs (1)

beremagene geperpavec (VYJUVEK) (2023 NDA)

Drugs in Phase 3 Trials (1)

beremagene geperpavec (VYJUVEK) (2 trials)

Drugs in Phase 2 Trials (2)

hsv1-col7 (1 trial)

TGM1 (2 trials)

Drugs in Phase 1 Trials (4)

kb301 (1 trial)

kb407 (2 trials)

kb408 (1 trial)

kb707 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 1)

Atrophy (Phase 1)

Cicatrix, Hypertrophic (Phase 1)

Epidermolysis Bullosa (Phase 3)

Epidermolysis Bullosa Dystrophica (Phase 3)

Ichthyosiform Erythroderma, Congenital (Phase 2)

Ichthyosis (Phase 2)

Ichthyosis, Lamellar (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 7